Álmos Klekner
A5029794929- Glioma Diagnosis and Treatment
- Hedgehog Signaling Pathway Studies
- Chromatin Remodeling and Cancer
- MicroRNA in disease regulation
- Cell Adhesion Molecules Research
- Meningioma and schwannoma management
- Microtubule and mitosis dynamics
- Cancer Genomics and Diagnostics
- Ocular Oncology and Treatments
- Cancer-related molecular mechanisms research
- Extracellular vesicles in disease
- Cancer Cells and Metastasis
- Caveolin-1 and cellular processes
- Genomics and Chromatin Dynamics
- Neuroblastoma Research and Treatments
- RNA Research and Splicing
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Surgical Oncology
- Microfluidic and Capillary Electrophoresis Applications
- Cancer, Hypoxia, and Metabolism
- Nosocomial Infections in ICU
- Innovative Microfluidic and Catalytic Techniques Innovation
- Cancer Mechanisms and Therapy
- Proteoglycans and glycosaminoglycans research
- Circular RNAs in diseases
University of Debrecen
2016-2025
Princess Margaret Cancer Centre
2016
Hospital for Sick Children
2011-2016
SickKids Foundation
2011-2016
British Columbia Children's Hospital
2016
McGill University
2011-2013
McMaster University
2013
University Medical Center Hamburg-Eppendorf
2013
Universität Hamburg
2013
St. Joseph's Hospital and Medical Center
2013
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique...
Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through inclusion molecular subgroup profiles.We determined affiliation, mutation status, and clinical outcome a discovery cohort 397 medulloblastomas. subsequently validated our results on an independent 156 medulloblastomas.TP53 are enriched wingless (WNT; 16%) sonic hedgehog (SHH; 21%) medulloblastomas virtually absent subgroups 3 4 tumors (P < .001). Patients...
Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, histologic variant. Stark prognostic genetic differences among the subgroups suggest that subgroup-specific biomarkers could improve prognostication.Molecular were identified from a discovery set 673 medulloblastomas 43 cities around world. Combined risk stratification models...
Recurrent mutations affecting the histone H3.3 residues Lys27 or indirectly Lys36 are frequent drivers of pediatric high-grade gliomas (over 30% HGGs). To identify additional driver in HGGs, we investigated a cohort 60 HGGs using whole-exome sequencing (WES) and compared them to 543 exomes from non-cancer control samples. We identified SETD2, H3K36 trimethyltransferase, 15% result that was genome-wide significant (FDR = 0.029). Most SETD2 alterations were truncating mutations. Sequencing...
Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a biology natural history. The therapeutic value of cytoreductive surgery radiation therapy for posterior after accounting subgroup is not known.Four independent nonoverlapping retrospective cohorts ependymomas (n = 820) were profiled using genome-wide methylation arrays. Risk stratification models designed based on known clinical newly described biomarkers identified by multivariable...
Abstract Glioblastoma is an aggressive form of brain cancer with well-established patterns intra-tumoral heterogeneity implicated in treatment resistance and progression. While regional single cell transcriptomic variations glioblastoma have been recently resolved, downstream phenotype-level proteomic programs yet to be assigned across glioblastoma’s hallmark histomorphologic niches. Here, we leverage mass spectrometry spatially align abundance levels 4,794 proteins distinct histologic 20...
Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT medulloblastoma have not been described. Hence, we sought describe these their impact a subgroup-specific manner. We analyzed by direct sequencing genotyping 466 medulloblastomas. The mutational distributions determined according subgroup affiliation, demographics, clinical,...
Oncogenic BRAF/Ras or NF1 loss can potentially trigger oncogene-induced senescence (OIS) through activation of the mitogen-activated protein kinase (MAPK) pathway. Somatic genetic abnormalities affecting this pathway occur in majority pilocytic astrocytomas (PA), most prevalent brain neoplasm children. We investigated whether OIS is induced PA.We tested expression established markers three independent cohorts sporadic PA. also assessed for vitro, using forced wild-type and V600E-mutant BRAF...
Abstract Sonic hedgehog medulloblastoma encompasses a clinically and molecularly diverse group of cancers the developing central nervous system. Here, we use unbiased sequencing transcriptome across large cohort 250 tumors to reveal differences among molecular subtypes disease, demonstrate previously unappreciated importance non-coding RNA transcripts. We identify alterations within cAMP dependent pathway ( GNAS , PRKAR1A ) which converge on GLI2 activity show that 18% have genetic event...
Matrix metalloproteinase-9 (MMP-9) degrades the extracellular matrix, contributes to tumour cell invasion and metastasis, its elevated level in brain tissues indicates poor prognosis. High-risk tissue biopsy can be replaced by liquid biopsy; however, blood-brain barrier (BBB) prevents tumour-associated components from entering peripheral blood, making development of blood-based biomarkers challenging. Therefore, we examined MMP-9 content small vesicles (sEVs)-which cross BBB are stable body...
Overexpression of PARP1 exists in various cancers, including glioblastoma (GBM). Although inhibition is a promising therapeutic target, no comprehensive study has addressed PARP1's expression characteristics and prognostic role regarding molecular heterogeneity astrocytomas GBM. Our aim was to evaluate associations with survival, WHO grade, lineage specific markers, GBM transcriptomic subtypes. We collected genomic clinical data from the latest glioma datasets The Cancer Genome Atlas...